CD8A and neoplasm: In addition, because CMV can establish a latent/persistent infection, a vaccine strain expressing a tumor antigen could continue to expand the patient’s circulating tumor-specific CD8+ T cell pool over time [11], potentially generating enough of a response to control tumor growth in a prophylactic or therapeutic setting and thwart metastatic growth at distant sites from the primary tumor.